Clovis Oncology

$4.52
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (+1.14%) Today
+$0.08 (+1.80%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell CLVS and other stocks, options, and ETFs commission-free!

About CLVS

Clovis Oncology, Inc. Common Stock, also called Clovis Oncology, is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. The listed name for CLVS is Clovis Oncology, Inc. Common Stock.

CEO
Patrick J. Mahaffy
Employees
484
Headquarters
Boulder, Colorado
Founded
2009
Market Cap
392.14M
Price-Earnings Ratio
Dividend Yield
Average Volume
4.58M
High Today
$4.57
Low Today
$4.35
Open Price
$4.41
Volume
4.68M
52 Week High
$17.37
52 Week Low
$3.62

Collections

CLVS Earnings

-$1.89
-$1.26
-$0.63
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 22, Pre-Market

You May Also Like